ABB India bags order to automate Reliance Life Sciences biopharmaceutical facilities
RLS' 160 acre facility at Nashik will house manufacturing plants for plasma proteins, biopharmaceuticals, oncology pharmaceuticals and vaccines.
New Delhi: ABB India has announced that it has secured a major automation contract from Reliance Life Sciences (RLS) to automate its new manufacturing plants in Nashik. However, the company did not disclose the value of the order.
ABB India has secured a major automation contract from Reliance Life Sciences (RLS) to automate its new manufacturing plants in Nashik, Maharashtra, a company statement said.
RLS' 160-acre facility at Nashik will house manufacturing plants for plasma proteins, biopharmaceuticals, oncology pharmaceuticals and vaccines.
Large-scale biotechnology production presents distinct and complex process and automation challenges.
These processes adhere to strict regulatory guidelines to ensure product quality, and ABB's System 800xA solution reduces manufacturing errors and ensures high-quality yields.
It connects seamlessly with various skid systems and is used extensively for seamless operator interaction, batch control and production information on the factory floor.
"We are proud to partner with Reliance Life Sciences on this critical project. This collaboration will reinforce our position in the pharma and life sciences market, where, as a technology provider, we see tremendous potential for growth and innovation," said G Balaji, SVP, Head of Energy Industries, ABB India.
"Reliance Life Sciences has a tradition of leveraging automation technologies in its manufacturing processes as part of its larger objectives in quality and productivity," Reliance Life Sciences President KV Subramaniam said.
Reliance Life Sciences is a research-driven organization developing business opportunities in bio-therapeutics (plasma proteins, biosimilars and novel proteins), pharmaceuticals (later-generation, oncology generics), clinical research services, regenerative medicine (stem cells therapies) and molecular medicine.
Reliance Life Sciences is part of the Promoter Group of Reliance Industries Limited.
Read also: IIT Kanpur licenses gene therapy to Reliance Life Sciences
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd